benzgalantamine

Benzgalantamine is a prodrug of galantamine, designed as a next-generation acetylcholinesterase inhibitor for the treatment of mild-to-moderate dementia in adults with Alzheimer's disease. It is administered orally as a delayed-release tablet and becomes active after hepatic metabolism, releasing galantamine systemically. This design allows benzgalantamine to bypass cholinergic receptors in the gastrointestinal tract, significantly reducing GI-related side effects compared to traditional acetylcholinesterase inhibitors. Once activated, it increases central nervous system acetylcholine levels by inhibiting acetylcholinesterase, thereby enhancing cholinergic neurotransmission and improving cognitive function. Benzgalantamine was approved by the FDA in July 2024 and is marketed under the brand name Zunveyl[1][2][3][6][9][10].

Brand names

Zunveyl

Other names

galantamine benzoateMemogain